SK Biopharmaceuticals Co., Ltd. (KRX: 326030)

Market Cap	9.33T
Revenue (ttm)	465.06B
Net Income (ttm)	33.80B
Shares Out	78.31M
EPS (ttm)	431.11
PE Ratio	276.49
Forward PE	90.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	788,761
Open	109,500
Previous Close	109,400
Day's Range	108,100 - 118,000
52-Week Range	72,600 - 119,500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, w...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 241
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 326030

Financial Performance

In 2023, SK Biopharmaceuticals's revenue was 354.89 billion, an increase of 44.16% compared to the previous year's 246.18 billion. Losses were -32.88 billion, -76.42% less than in 2022.